Orin
DOWNYSE·Chemicals

Dow Inc. DOW

Market cap $20.3BP/E —no earnings to divide byGross margin 9.8%Reports Thu 22 Oct, before the open
$28.04
−0.52 (−1.80%)live 11:20 ET
52-wk $20.65 – $42.74
Watch
Orin's take
0.50conviction · moderate
Refreshed 30 Aug · take v7. A new filing or a print queues the next refresh.

Dow Inc. remains a hold as FY2025 confirmed severe fundamental deterioration — a $2.62B net loss (EPS -$3.69), gross margin collapsing to 5.99% from 10.37% a year earlier, and negative $1.447B free cash flow with total debt climbing to $19.6B against $16.0B equity. The stock trades at a ~69% P/S discount to peers (0.53x vs 1.73x median) and insiders have been net buyers ($35.8M over 24 months including the CEO's July 2026 acquisition), but the 16.94x EV/EBITDA sits ~20% above the peer median despite the company being loss-making, and smart money reduced its score from 0.0495 to 0.0035 as of the quarter ended 2026-06-30 — institutions are trimming while the stock drifts below its 200-day MA ($31.28) with a negative MACD histogram.

The risk-reward is balanced: cyclical recovery potential versus an ongoing cash burn and margin compression that could persist.

What could go wrong

  • Margin compression continues. Gross margin fell from 10.37% in FY2024 to 5.99% in FY2025 with operating margin near zero at 0.65%; further erosion would deepen losses and erode equity.
  • Balance sheet stress. Total debt rose to $19.598B against $16.008B equity, while free cash flow is negative at -$1.447B, raising refinancing and deleveraging concerns if the downturn persists.
  • Institutional outflow. Smart money score dropped from 0.0495 to 0.0035 as of the quarter ended 2026-06-30, with fund count falling from 61 to 59 — signaling reduced conviction among sophisticated holders.
  • Cyclical trough versus structural decline. Revenue has declined four straight years ($56.9B in FY2022 to $39.97B in FY2025); if this reflects structural rather than cyclical weakness, the valuation discount is a trap.

What would change my mind

Margin recovery. Gross margin rebounds above 10% and operating margin exceeds 3% on a quarterly or full-year basis, signaling cyclical recoverybullish
Free cash flow inflection. Quarterly or annual free cash flow turns positive, indicating capex cycle winding down and reduced cash burnbullish
Further operating loss. Operating income turns negative on a quarterly or annual basis, confirming the 0.65% FY2025 operating margin is not a floorbearish
Credit rating downgrade or dividend reduction. Rating agencies downgrade Dow's debt or the company cuts shareholder returns to preserve liquidity amid negative FCFbearish

Where this comes from: FMP fundamentals FY2025 · derived_metrics FY2025 vs FY2024 · FMP fundamentals FY2025 · peer_relative. Orin's read on DOW; not advice.

Twelve months actual closes to 2026-09-24 · actual filings

Sept 25Nov 25Jan 26Mar 26May 26Jul 26

50-day average 200-day average · volume below

Largest holders · 13F Q2 2026

Money flow
FilerPositionOf fund
Vanguard Capital Management$1.3B0.0% of fund
State Street$1.0B0.0% of fund
Vanguard Portfolio Management$954.5M0.0% of fund
Geode Capital Management$525.4M0.0% of fund
Two Sigma Investments$489.0M0.4% of fund
Capital World Investors$430.8M0.1% of fund

91 filers · quarter ended Q2 2026 · positions, not flows

Insiders, last 24 months: 88 Form 4 filings, net $35.8M. Of the 50 on hand, none was an open-market trade— the rest are grants, option exercises and tax withholding.

Ask Orin about DOW

its filings · its transcripts · its numbers

Orin answers questions about DOW from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

Start 3 free days →

Where it trades

vs its own 5y · Basic Materials
MetricNowOwn medianSector
EV/EBITDA16.3×8.3×—
P/S0.50×0.66×—
P/B0.8×1.8×—

Its P/E sits below all 5 of the last 5 years (−1.42σ from its own mean).

What Wall Street published

36 firms · 2026-09-24
Consensus target

$35

$28 – $45 · +24% against today's price

How they rate it
  • 11 buy or overweight
  • 20 hold
  • 5 underweight or sell

The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.

Against the companies it is compared to

median P/E 50.5× of 6 peers
CompanyMarket capP/EEV/EBITDAGrossNetROE
DOWDow Inc.$21B—16.3×9.8%-2.9%-7%
ALBAlbemarle Corporation$13B225.5×10.7×23.9%3.8%2%
DDDuPont de Nemours, Inc.$18B283.2×14.3×34.4%0.7%0%
IFFInternational Flavors & Fragrances Inc.$22B78.8×18.6×37.5%2.9%2%
LYBLyondellBasell Industries N.V.$19B—16.4×13.2%-1.1%-3%
PPGPPG Industries, Inc.$24B15.1×10.6×40.1%9.6%19%
RPMRPM International Inc.$13B19.0×11.4×41.4%8.4%21%
RSReliance Steel & Aluminum Co.$20B22.3×14.1×26.9%5.7%12%

The median is of the 6 peers listed above and nothing else — check it against the column. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.

What it has traded at

P/E by fiscal year
FY15 6.1×FY24 25.6×

What its sector has traded at

Basic Materials
FY14 23.8×FY26 28.6×

Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.

Discounted cash flow

not recomputed since
ModelFair valueAgainstComputed
Standard DCF$70$34.05 · +105%2026-06-10
Levered DCF$27$34.05 · −22%2026-06-10

The vendor’s intrinsic-value models. Treat them as a low-growth anchor — for a fast grower the market routinely pays well above a DCF. These were computed against the price in the “against” column, not today’s.

Every estimate on one scale

price $28.04
52-week range$21 – $43
Analyst targets$28 – $45
Standard DCF$70 as of 2026-06-10, when it was $34.05
Levered DCF$27 as of 2026-06-10, when it was $34.05

The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.